Skip to main content

09-14-2017 | Heart failure | EASD 2017 | News

News in brief

Steno-2 shows power of intensive treatment to avert HF


medwireNews: Results from Steno-2 show that intensive multifactorial treatment reduces the risk for heart failure (HF) in patients with type 2 diabetes and microalbuminuria.

Speaking at the EASD annual meeting in Lisbon, Portugal, Jens Øllgaard (Slagelse Hospital, Denmark) described HF in diabetes as “frequent, fatal, and forgotten.” And he added that as many Steno-2 participants had HF during follow-up as had myocardial infarction or stroke, making it an extremely important complication of diabetes. 

But the post-hoc analysis of the Steno-2 trial he presented today shows that intensive treatment targeting risk factors for diabetic complications has a marked protective effect against hospitalization for HF, reducing the risk by 76% after accounting for age, gender, pro-brain natriuretic peptide, and ejection fraction. The number needed to treat for 1 year to prevent one event was 63.

In all, 13% of the 80 patients who received the intensive intervention were hospitalized for HF, compared with 30% of the 80 who received conventional treatment, giving annual rates of 0.8% versus 2.4%. The randomized period lasted for 7.8 years, after which all patients were moved onto the intensive intervention.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

See also:


New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

GLP-1 receptor agonists

Browse the latest news, clinical trial updates, and expert commentary.